E-ISSN 2231-3206 | ISSN 2320-4672
 
2023, Vol: 13, Issue: 12
13 / 12Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded



Original Research 


Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris – A randomized controlled trial

Meghana D, Laxminarayana Kamath, Revathi T N.

Abstract
Background: Dermatophyte infections are very common and they manifest as tinea corporis/cruris. Among the various topical antifungal drugs available, the first option being terbinafine and new generation azoles as sertaconazole professes superior activity.

Aim and Objective: The objective of the study was to evaluate efficacy and safety of topical terbinafine versus topical sertaconazole in tinea cruris patients.

Materials and Methods: We conducted a randomized control trial from May 2019 to September 2019 in the Department of Dermatology, Bangalore Medical College and Research Institute. Over 60 patients with tinea cruris randomly divided into two groups of 30 each. Group A applied topical 1% terbinafine cream and Group B applied topical 2% sertaconazole cream for a period of 4 weeks. Follow-up visit of patients was at 2 and 4 weeks to assess efficacy parameters (mycological and clinical cure) and safety assessment done by recording adverse reactions.

Results: Thirty patients were analyzed in each group. About 98.3% in the terbinafine group and 99.4% in the sertaconazole group showed significant improvement in signs and symptoms from baseline to 4 weeks (P < 0.001). The mean difference of the total score of all parameters (baseline to 4 weeks) for the terbinafine group was 4.06 ± 0.79 and the sertaconazole group was 4.60 ± 0.95, respectively. Mycological cure was achieved by all patients. Both drugs were well tolerated. No serious adverse drug events in both the groups.

Conclusion: Terbinafine was equal in efficacy and safety to newer azole – sertaconazole in treating patients with tinea cruris. However, sertaconazole has showed a better response to
therapy as compared to terbinafine.

Key words: Dermatophyte Infections; Tinea Cruris; Topical Antifungals; Sertaconazole; Terbinafine


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Meghana D
Articles by Laxminarayana Kamath
Articles by Revathi T N
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

D M, Kamath L, N RT. Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris – A randomized controlled trial. Natl J Physiol Pharm Pharmacol. 2021; 11(1): 13-16. doi:10.5455/njppp.2021.10.07180202022082020

Web Style

D M, Kamath L, N RT. Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris – A randomized controlled trial. https://www.njppp.com/?mno=96512 [Access: December 03, 2023]. doi:10.5455/njppp.2021.10.07180202022082020

AMA (American Medical Association) Style

D M, Kamath L, N RT. Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris – A randomized controlled trial. Natl J Physiol Pharm Pharmacol. 2021; 11(1): 13-16. doi:10.5455/njppp.2021.10.07180202022082020


Vancouver/ICMJE Style

D M, Kamath L, N RT. Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris – A randomized controlled trial. Natl J Physiol Pharm Pharmacol. (2021), [cited December 03, 2023]; 11(1): 13-16. doi:10.5455/njppp.2021.10.07180202022082020


Harvard Style

D, M., Kamath, . L. & N, . R. T. (2021) Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris – A randomized controlled trial. Natl J Physiol Pharm Pharmacol, 11 (1), 13-16. doi:10.5455/njppp.2021.10.07180202022082020


Turabian Style

D, Meghana, Laxminarayana Kamath, and Revathi T N. 2021. Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris – A randomized controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 11 (1), 13-16. doi:10.5455/njppp.2021.10.07180202022082020


Chicago Style

D, Meghana, Laxminarayana Kamath, and Revathi T N. "Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris – A randomized controlled trial." National Journal of Physiology, Pharmacy and Pharmacology 11 (2021), 13-16. doi:10.5455/njppp.2021.10.07180202022082020


MLA (The Modern Language Association) Style

D, Meghana, Laxminarayana Kamath, and Revathi T N. "Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris – A randomized controlled trial." National Journal of Physiology, Pharmacy and Pharmacology 11.1 (2021), 13-16. Print. doi:10.5455/njppp.2021.10.07180202022082020


APA (American Psychological Association) Style

D, M., Kamath, . L. & N, . R. T. (2021) Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris – A randomized controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 11 (1), 13-16. doi:10.5455/njppp.2021.10.07180202022082020


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

  National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal.  The journal is having open access polic ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Publisher

publishernjppp@gmail.com

 

Editorial query

editornjppp1@gmail.com

MOB - 8780040272